Wavena Raises KRW 200M Seed Led by Seoul National University Technology Holdings

Wavena Closes Seed Round

Wavena (웨이비나), a South Korean digital healthcare startup, has raised a seed round of KRW 200 million. Seoul National University Technology Holdings led the round and was the sole investor listed. The funding was announced on October 8, 2026.

What the Company Does

Wavena was founded in 2026 and is based in Seoul. The company develops AI capable of predicting more than 30 blood biomarkers from a 10-second ECG measurement without drawing blood.

Its models are trained on a proprietary database of over 4 million ECG-blood matched clinical records from the Seoul National University Hospital network. According to the company, the models achieve AUROC scores of 0.89–0.92 across nine biomarkers, including hyperkalemia, kidney function, anemia and heart failure.

Commercialization Path

Wavena is commercializing Wavena Medical, a clinical decision-support system for hemodialysis and critical care. Alongside that clinical product, the company is developing consumer, veterinary and non-invasive glucose monitoring products.

Deal Context

The round is a seed-stage financing led by an investor affiliated with the university hospital network whose clinical data underpins the company's models. That relationship is a notable structural feature for acquisition-oriented observers: the proprietary dataset and the clinical validation pathway are central to the company's positioning in non-invasive blood biomarker prediction.

Summary

• Company: Wavena (웨이비나)
• Headquarters: Seoul, South Korea
• Founded: 2026
• Round: Seed
• Amount: KRW 200 million
• Lead investor: Seoul National University Technology Holdings
• Announcement date: October 8, 2026
• Technology: AI predicting 30+ blood biomarkers from a 10-second ECG without blood draw
• Data basis: Proprietary database of over 4 million ECG-blood matched clinical records from the Seoul National University Hospital network
• Reported performance: AUROC of 0.89–0.92 across nine biomarkers, including hyperkalemia, kidney function, anemia and heart failure
• Products: Wavena Medical (clinical decision-support for hemodialysis and critical care); consumer, veterinary and non-invasive glucose monitoring products